ABT vs SNSE

Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.

Sensei Biotherapeutics Inc.

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.